Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
After Profitable Year, Genomic Health to Invest in New Products, Overseas Market, Next-Gen Sequencing
February 16, 2011
As the company looks to 2011 and beyond, it plans to continue to invest in growing its test menu, expanding its business overseas, and advancing sequencing efforts to ultimately develop the next generation of Oncotype DX tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Genomic Health Updates Investors on Timeline for DCIS, Colon Cancer, Prostate Cancer Tests
September 29, 2010 / Pharmacogenomics Reporter - Genomic Health Partners with OncoMed to Grow Companion Dx, NGS Reach
May 9, 2012 / Pharmacogenomics Reporter - Genomic Health Inks PGx Alliance with OncoMed
May 2, 2012 / GenomeWeb Daily News - Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity
February 8, 2012 / Pharmacogenomics Reporter - Genomic Health Expanding Sales Force by 20 Percent; Starts Prostate Dx Studies
January 9, 2012 / GenomeWeb Daily News